Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease
Open Access
- 5 April 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (10) , 1689-1699
Abstract
Myxopapillary ependymoma (MPE) is a heterogeneous disease regarding histopathology and outcome. The underlying molecular biology is poorly understood, and markers that reliably predict the patients’ clinical course are unknown. We assembled a cohort of 185 tumors classified as MPE based on DNA methylation. Methylation patterns, copy number profiles, and MGMT promoter methylation were analyzed for all tumors, 106 tumors were evaluated histomorphologically, and RNA sequencing was performed for 37 cases. Based on methylation profiling, we defined two subtypes MPE-A and MPE-B, and explored associations with epidemiological, clinical, pathological, and molecular characteristics of these tumors. MPE-A occurred at a median age of 27 years and were enriched with tumors demonstrating papillary morphology and MGMT promoter hypermethylation. Half of these tumors could not be totally resected, and 85% relapsed within 10 years. Copy number alterations were more common in MPE-A. RNA sequencing revealed an enrichment for extracellular matrix and immune system-related signatures in MPE-A. MPE-B occurred at a median age of 45 years and included many tumors with a histological diagnosis of WHO grade II and tanycytic morphology. Patients within this subtype had a significantly better outcome with a relapse rate of 33% in 10 years (P = 3.4e-06). We unraveled the morphological and clinical heterogeneity of MPE by identifying two molecularly distinct subtypes. These subtypes significantly differed in progression-free survival and will likely need different protocols for surveillance and treatment.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SCHU2442/8-1)
- Gert und Susanna Mayer Stiftung
- Fördergemeinschaft Kinderkrebs-Zentrum Hamburg
- Friedberg Charitable Foundation
- Making Headway Foundation
This publication has 28 references indexed in Scilit:
- Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomesJournal of Neuro-Oncology, 2016
- Outcome Predictors in the Management of Spinal Myxopapillary Ependymoma: An Integrative Survival AnalysisWorld Neurosurgery, 2015
- Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age GroupsCancer Cell, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer NetworkNeuro-Oncology, 2014
- Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome AtlasCancer Immunology Research, 2013
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-statusActa Neuropathologica, 2012
- Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT databaseJournal of neurosurgery. Pediatrics, 2010
- Unique Molecular Characteristics of Pediatric Myxopapillary EpendymomaBrain Pathology, 2010
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005